Individual variation in D2 dopamine receptor occupancy in clozapine- treated patients

American Journal of Psychiatry

Volumn 153, Issue 12, 1996, Pages 1571-1578

  Pickar, David ^a   Su, Tung Ping ^b   Weinberger, Daniel R ^b   Coppola, Richard ^b   Malhotra, Anil K ^b   Knable, Michael B ^b   Lee, Kan Sam ^b   Gorey, Julia ^b   Bartko, John J ^b   Breier, Alan ^b   Hsiao, John ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; IODINE 123; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; BINDING SITE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIGAND BINDING; MALE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BINDING COMPETITION; BLOOD; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; METABOLISM; MIDDLE AGED; PSYCHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; BENZAMIDES; BINDING, COMPETITIVE; CLOZAPINE; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0029658718     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.12.1571     Document Type: Article

References (55)

1. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living brain by PET. Science 1986; 231:258-261
2. Farde L, Wiesel F-A, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71-76
3. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
4. Seeman P, Lee T, Chau-Wong M: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717-719
5. 18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988; 23: 653-663
6. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989; 99:463-472
7. 76Br-bromolisuride. Br J Psychiatry 1991; 158:346-350
8. 2 dopamine receptor imaging agent. J Nucl Med 1989; 30:88-92
9. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
10. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106: 433-438
11. Nordstrom A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-235
12. 2-receptor occupancy during antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14:759-767
13. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994; 55(Sept suppl B):67-69
14. 11C]raclopride. Psychopharmacology (Berl) 1992; 107:23-29
15. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
16. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
17. Brucke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S: Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics (letter). Lancet 1992; 339:497
18. - dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340:199-202; correction, 340:380
19. 123IIBZM SPET (single photon emission tomography) study, Psychol Med 1993; 23:791-797
20. 2 receptor occupancy in vivo and response to the new antipsychotic risperidone (letter). Br J Psychiatry 1993; 163:833-834
21. Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M: Sriatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry 1994; 36:627-629
22. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients: an 123I-IBZM single photon emission computerized tomography study. Br J Psychiatry 1994; 164:16-26
23. Knable MB, Jones DW, Coppola R, Hyde TM, Lee KS, Gorey J, Weinberger DR: Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995; 36:1216-1225
24. Pickar D, Hsiao J: Clozapine treatment of schizophrenia. JAMA 1995; 274:981-983
25. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler JS, Cooper TB: Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989; 46:482-484
26. Coppens HJ, Sloof CJ, Paans AM, Wiegman T, Vaalburg W, Korf J: High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 1991; 29:629-634
27. 2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm 1991; 86:163-173
28. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908
29. 123I)-IBZM binding to the D2 receptor in nonhuman primates. Synapse 1992; 10:177-184
30. Laruelle M, Ahi-Dargham A, van Dyck CH, Rosenblatt W, Ponce YZ, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HK, Innis RB: SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36:1182-1190
31. 11C]raclopride in the human brain. Synapse 1994; 16:225-262
32. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
33. 123I-IBZM: a potential dopamine D2 receptor imaging agent. J Labelled Compounds and Radiopharmaceuticals 1989; 27:691-700
34. Knable MB, Gonzalex J, Coppola R, Jones DW, Nawroz S, Gorey J, Weinberger DR: 1-123 IBZM SPECT in neuroleptic-free schizophrenic patients (abstract). Schizophr Res 1995; 15:88
35. Miller DD, Fleming F, Holman TL, Perry PJ: Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55(Sept suppl B):78-81
36. Jann MW, Grinsley SR, Gray EC, Chang WH: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161-176
37. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lysons D, Cohen BM: Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993; 9:117-124
38. 11C]raclopride. Arch Gen Psychiatry 1990; 47:213-219
39. Shore D: Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995; 21:333-338
40. Grace AA: The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 1992; 36:91-131
41. Pickar D: Perspective on time-dependent model of neuroleptic action. Schizophr Bull 1988; 14:255-268
42. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM: Neuroleptic-induced decrease in plasma homovanillic acid levels and antipsychotic activity in schizophrenic patients. Science 1984; 225:954-957
43. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy AR, Breier A, Linnoila M, Paul SM: Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 1986; 43:669-676
44. 11C-raclopride/ PET (abstract), in Proceedings of the Society for Neuroscience. Washington, DC, Society for Neuroscience, 1994, p 25
45. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1992; 13: 350-356
46. Meltzer HY, Stockmeier CA: In vivo occupancy of dopamine receptors by antipsychotic drugs. Arch Gen Psychiatry 1992; 40: 588-589
47. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15:264-270
48. Kessler RM, Mason NS, Votaw JR, De Paulis T, Clanton JA, Ansari MS, Schmidt DE, Manning RG, Bell RL: Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 1992; 223:105-107
49. 2 receptor occupancy in clozapine-treated patients demonstrated by PET. Psychopharmacology(Berl) 1993; 110:365-367
50. 2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246
51. Pickar D, Owen RR, Litman RR, Konicki PE, Gutierrey R, Rapaport MH: Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
52. Litman R, Su T-P, Potter WZ, Hong WW, Pickar D: Idazoxan, an alpha-2 antagonist, augments response to typical neuroleptics in treatment-resistant schizophrenia. Br J Psychiatry 1996; 168: 571-579
53. Pickar D, Litman RE, Hong WW, Su JP, Weissman EM, Hsiao JK, Potter WZ: Clinical response to clozapine in patients with schizophrenia (letter). Arch Gen Psychiatry 1994; 51:159-160
54. Pickar D: Prospects for the pharmacotherapy of schizophrenia. Lancet 1995; 345:557-562
55. Roth BL, Craigo SC, Choudhary MS: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268:1403-1410